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Abstract
Introduction: A combination of carboplatin and paclitaxel is often used as first line chemotherapy for treatment of
ovarian cancer. Therefore the use of imaging biomarkers early after initiation of treatment to determine treatment
sensitivity would be valuable in order to identify responders from non-responders. In this study we describe the non-
invasive PET imaging of glucose uptake and cell proliferation using 2-deoxy-2-[18F]fluoro-D-glucose (FDG) and 3’-
deoxy-3’-[18F]fluorothymidine (FLT) for early assessment of treatment response in a pre-clinical mouse model of
human ovarian cancer treated with carboplatin and paclitaxel.
Methods: In vivo uptake of FLT and FDG in human ovarian cancer xenografts in mice (A2780) was determined
before treatment with carboplatin and paclitaxel (CaP) and repeatedday 1, 4 and 8 after treatment start. Tracer
uptake was quantified using small animal PET/CT. Tracer uptake was compared with gene expression of Ki67, TK1,
GLUT1, HK1 and HK2.
Results: Tumors in the CaP group was significantly smaller than in the control group (p=0.03) on day 8. On day 4
FDG SUVmax ratio was significantly lower in the CaP group compared to the control group (105±4% vs 138±9%;
p=0.002) and on day 8 the FDG SUVmax ratio was lower in the CaP compared to the control group (125±13% vs
167±13%; p=0.05). On day 1 the uptake of FLT SUVmax ratio was 89±9% in the CaP group and 109±6% in the
control group; however the difference was not statistically significant (p=0.08).
Conclusions: Our data suggest that both FDG and FLT PET may be used for the assessment of anti-tumor effects
of a combination of carboplatin and paclitaxel in the treatment of ovarian cancer. FLT provides an early and transient
signal and FDG a later and more prolonged response. This underscores the importance of optimal timing between
treatment and FLT or FDG imaging since treatment response may otherwise be overlooked.
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Introduction
Ovarian cancer is the second most common gynecological
malignancy and the leading cause of gynecological cancer
related death in women in Europe and the Unites States [1,2].
The combination of carboplatin and paclitaxel is commonly
used as first-line chemotherapy for treatment of ovarian cancer
[3]. The overall response rate of carboplatin and paclitaxel
therapy is 60-80% and although this response rate is relatively
high compared to standard treatment of other malignancies
several patients does not respond to the therapy [4,5]. In the
responding patient population many patients relapse and,
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dependent on the time from the first treatment until relapse, a
second treatment regime with platinum-based chemotherapy
may be initiated. The response rate for treatment of patients
with relapse is 20-30% if the platinum free interval is 6-12
months and >60% for platinum-free intervals of 12-18 months
[5].
Evaluation of therapeutic response is frequently based on
Response Evaluation Criteria in Solid Tumors (RECIST)
guidelines where evaluation of treatment response is based on
morphological imaging with computed tomography (CT) or
magnetic resonance imaging (MRI) [6]. Anatomical imaging
with CT and MRI does not provide information on the early
biological processes induced by the therapy and decrease in
tumor sizes is often first detectable later in the treatment
course. However, early biological changes might be predictive
for clinical regression before treatment effect can be assessed
by anatomical imaging. Therefore, determination of tumor
sensitivity early during treatment and by that identification of
responders and non-responders could potentially allow for a
personalized treatment approach as therapy could be modified
in the non-responding patients.
Positron emission tomography (PET) imaging is a non-
invasive, whole body technique where it is possible to measure
physiological processes in vivo thereby circumventing the
process of acquiring serial biopsies. Identification of a PET
tracer that early after initiation of an anti-cancer treatment gives
information that can predict treatment outcome is therefore of
considerable interest. The comparison of tracer uptake in
tumors before and in the beginning of treatment is used for
monitoring the biological processes and responses evoked by
the treatment. The glucose analogue 2-deoxy-2-[18F]fluoro-D-
glucose (FDG) and the thymidine analogue 3’-deoxy-3’-
[18F]fluorothymidine (FLT) are two of the most widely studied
PET tracers used for treatment monitoring.
Imaging of metabolism with the glucose analogue FDG is
used for diagnosis and staging of cancer and has high
diagnostic accuracy for various tumor types. FDG crosses the
cell membrane by glucose transporters whereby it is
phosphorylated by intracellular hexokinases (HK) which results
in intracellular trapping despite no further metabolism of the
phosphorylated FDG. Glucose transporters and hexokinases
are up-regulated in several cancer forms which lead to a high
FDG uptake in tumor compared to normal cells [7,8].
The thymidine analogue FLT is used for imaging of cell
proliferation with PET. FLT is incorporated into cells by the
pyrimidine salvage pathway paralleled with thymidine and after
uptake into cells FLT is phosphorylated by thymidine kinase 1
(TK1). The phosphorylation leads to intracellular trapping even
though the phosphorylated FLT is not being incorporated into
DNA [9]. The activity of TK1 is coupled to the cell cycle and it is
mainly expressed during the S-phase [10,11]. FLT uptake is
positively correlated with cell growth and TK1 activity [11-13]
and in several studies a positive correlation between FLT
uptake and tumor cell proliferation measured by Ki67
immunohistochemistry (IHC) is found [14-24].
FDG and FLT PET have in both pre-clinical and clinical
studies been evaluated as imaging biomarkers that can predict
and assess responses to various types of chemotherapeutic
agents in several tumor types [14,19,20,22,25-36]. The results
are variable, in some studies early changes in tracer uptake
predict later tumor regression and in other studies no changes
in tracer uptake are observed despite the treatment being
effective. The mechanisms behind changes in tracer uptake
after treatment initiation seem to be complex and dependent on
both the tumor type and mode of action of the anti-cancer drug.
In addition, the tumor baseline tracer avidity influences whether
or not FDG or FLT can be used for prediction of anti-cancer
treatment response e.g. in tumors with low baseline tracer
avidity, decrease in tracer uptake is difficult to determine.
Carboplatin belongs to the group of platinum based anti-
cancer agents causing intra-strand crosslinks in DNA which
affects DNA repair and replication. Carboplatin causes cell
cycle arrest in the G2 phase and induces apoptosis if the DNA
damage is not properly repaired [37]. Paclitaxel binds to and
stabilizes the microtubules which causes cell cycle arrest in the
G2/M phase and induction of apoptotic cell death [38].
Ovarian cancer is often positive on FDG PET; however, few
studies have studied prediction of ovarian cancer patient
outcome after initiation of anti-cancer therapy with FDG PET
[39]. In one study changes in FDG-PET uptake was predictive
of patient outcome after the first cycle of neo-adjuvant
chemotherapy consisting of carboplatin and paclitaxel
combination therapy [40]. FDG PET was more accurate than
either clinical or histopathologic response criteria or the tumor
marker cancer antigen 125 (CA125) to predict treatment
outcome. In another study, on the effect of neo-adjuvant
treatment with carboplatin and paclitaxel in patients with
ovarian cancer, it was found that in patients where the tumor
uptake of FDG was equal to normal surrounding tissue uptake
after 3 courses of chemotherapy these were more likely to
benefit from 3 additional courses of chemotherapy than
patients without normalization of FDG uptake [41].
Baseline FLT uptake has been analyzed in a small group of
ovarian cancer patients where FLT uptake was higher in
malignant compared to normal ovarian tissue [42]. In a pre-
clinical study FLT uptake was decreased following effective
mTOR inhibition with everolimus in a cisplatin-resistant ovarian
tumor mouse model [25]. In cisplatin-sensitive ovarian cancer
xenografts both FLT and FDG uptake are decreased day 4
after initiation of treatment with cisplatin [43]. However, to our
knowledge, no study has yet compared changes in FLT and
FDG after treatment with the combination of carboplatin and
paclitaxel in a pre-clinical ovarian tumor model. Results from
such a study would be clinically relevant since they could be
used for selection of PET tracer and imaging time-points.
The aim of this study was therefore to determine and
compare glucose uptake and cell proliferation by use of FDG
and FLT PET following treatment with a combination of
carboplatin and paclitaxel in a xenograft mouse model of
human ovarian cancer. The FDG uptake was compared with
gene expression of GLUT1, HK1 and HK2 and FLT uptake was
compared with gene expression of Ki67 and TK1.
FDG and FLT PET Imaging of CaP Treatment
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Materials and Methods
Tumor model
Animal care and all experimental procedures were performed
under the approval of the Danish Animal Welfare Council
(2006/561-1124). Eight week old female NMRI nude mice
(Taconic Europe, Lille Skensved, Denmark) were used for
generation of the A2780 xenograft model. All mice were
acclimatized for one week in the animal facility before injection
of tumor cells. The human ovarian carcinoma cell line A2780
was cultured in RPMI (Roswell Park Memorial Institute)
medium 1640 + GlutaMAX (Invitrogen, Carlsbad, CA, USA)
supplemented with 10% fetal calf serum (Biological Industries,
Israel) and 1% penicillin-streptomycin (Invitrogen) in 5% CO2 at
37°C. The cell line was tested free of mycoplasma. For
establishment of xenografts 107 cells were diluted in 100 μL
medium and mixed with 100 μL Matrixgel™ Basement
Membrane Matrix (BD Biosciences, San Jose, CA, USA) for
each tumor and injected into the left and right flank
respectively.
Experimental design
In vivo uptake of FDG and FLT in human ovarian cancer
xenografts in mice was determined. Four groups of mice were
used (4 mice/group). Baseline tumor sizes were approximately
100 mm3 on day -2. Two groups received a combination of
carboplatin (Hospira, Illinois, USA) and paclitaxel (Actavis,
Gentofte, Denmark) and two groups received vehicle (isotonic
saline). The control groups were identical with the control
groups in a previously published study as the two studies were
carried out in parallel [44]. Doses were 40 mg/kg ip for
carboplatin and 10 mg/kg iv for paclitaxel injected on day 0 and
5. One treatment group (n=8 tumors) and one control group
(n=5 tumors) received FDG scans and one treatment group
(n=6 tumors) and one control group (n=7 tumors) received FLT
scans. Baseline FDG or FLT PET scans were made before
treatment (day 0 or day -2) and repeated on day 1, 4 and 8
after start of treatment. Tracer uptake was in all cases
quantified using small animal PET/CT. During the experiments
the tumor sizes were measured by microCT [45,46]. On day 8
immediately after the last PET/CT scan all tumors were excised
and gene expression of GLUT1, HK1, HK2, Ki67 and TK1 were
subsequently measured by qPCR.
Synthesis of FDG and FLT
The radiosynthesis and quality control of FLT was performed
as previously described [47]. FDG was acquired from the daily
productions at Rigshospitalet (Copenhagen, Denmark).
microPET/CT imaging
For PET imaging mice were administered approximately 10
MBq of FDG or FLT by an intravenous injection. The tracers
were allowed to distribute for one hour while the animals were
awake. The mice receiving FDG scans were fasted overnight
before each FDG injection [48]. During the 10 minutes long
PET scans the mice were anaesthetized with 3% sevofluran
(Abbott Scandinavia AB, Solna, Sweden) in 35% O2. PET
scans were acquired with a MicroPET Focus 120 (Siemens
Medical Solutions, Malvern, PA, USA) and each PET scan was
followed by a microCT scan acquired with a MicroCAT® II
system (Siemens Medical Solutions) as previously described
[47]. The mice were kept anaesthetized in the same position
during the PET and CT scans allowing afterwards fusion of the
images in the Inveon software (Siemens Medical Solutions).
PET data were arranged into sinograms and subsequently
reconstructed with the maximum a posteriori (MAP)
reconstruction algorithm. The pixel size was 0.3 x 0.3 x 0.8 mm
and in the center field of view the resolution was 1.2 mm full-
width-at-half-maximum. The images were not corrected for
attenuation or scatter.
After fusion of PET and CT images several region of
interests (ROIs) were drawn on the CT images manually by
qualitative assessment covering the whole tumor in several of
the tomographic planes. Thereafter all ROIs were summed and
subsequently both tumor sizes and tracer uptake were
calculated. The whole tumor volume defined on the CT images
was therefore used for calculation of the PET tracer uptake.
Tracer uptake was quantified by standardized uptake value
(SUV) and the tracer uptake after treatment start was
calculated relative to baseline uptake. The formula (CT*W)/Dinj,
where CT is tissue radioactivity concentration, W is weight of
the animal and Dinj is injected dose, was used for SUV
calculations. SUVmean is a measure of the mean tissue
radioactivity concentration in the tumor and SUVmax is a
measure of the voxel within the ROI with the highest tracer
concentration. For both SUVmean and SUVmax the uptake
after treatment initiation is calculated relative to the uptake at
baseline before treatment initiation and therefore the terms
SUVmean ratio (SUVmean,after treatment/SUVmean,baseline)
and SUVmax ratio (SUVmax,after treatment/SUVmax,baseline)
were used.
Quantitative real-time polymerase chain reaction
(qPCR)
Total RNA was isolated with TRI reagent® following the
manufacturer’s instructions (Molecular Research Center Inc.,
OH, USA). RNA concentration was determined by NanoDrop
1000 (Thermo Fisher Scientific, Wilmington, DE, USA). RNA
(0.3 μg) was reversed transcribed using the Affinityscript™
QPCR cDNA Synthesis kit (Stratagene, La Jolla, CA, USA)
according to the manufacturer’s instructions.
All primers were designed in Beacon Designer (PREMIER
Biosoft, Palo Alto, CA, USA). Primer sequences are shown in
table 1. For each gene the primer concentrations were
optimized. All samples were run in triplicate and to each
sample a no-reverse transcriptional control (NoRT) was
included and on each plate a no-template control (NTC) was
included.
Gene expression was quantified on a Mx3000P® real-time
PCR system (Stratagene) using Brilliant® SYBR® Green
QPCR Master Mix (Stratagene). The thermal profile was: 10
minutes of denaturation at 95°C followed by 45 cycles of 30
seconds denaturation at 95°C, 1 minute of annealing at 60°C
and 1 minute extension at 72°C. A dissociation curve was
thereafter obtained by denaturation of the products for 1 minute
FDG and FLT PET Imaging of CaP Treatment
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at 95°C followed by a stepwise increase in temperature from
55°C to 95°C with steps of 0.5ºC/cycle where the duration of
each cycle was 18 seconds.
The qBase program was used for QPCR data analysis. The
relative quantification of the gene of interests (GOIs) was
presented as fold changes in the treatment group compared to
the control group on day 8 normalized to the geometric mean
of two reference genes [49]. The two most stable reference
genes were found from a panel of 12 candidate genes in the
human reference gene panel (TATAA Biocenter AB, Göteborg,
Sweden) using the geNorm algorithm.
Statistical analysis
Unpaired students t-test was used for comparison between
treatment and control groups. No correction for multiple
comparisons was applied. Calculations were made in SPSS 20
(IBM Corporation, Armonk, New York, USA). Data are reported
as mean±SEM and p<0.05 was considered statistically
significant.
Table 1. qPCR primer sequences.
Name NCBI NM_ID Forward primer (5’-3’) Reverse primer (5’-3’)
GUSB NM_000181 tgagcaagactgatacca gctagaatagatgaccacaa
HPRT1 NM_000194 caaagcctaagatgagagt gccacagaactagaacat
GLUT1 NM_006516 catcatcttcatcccggc ctcctcgttgcggttgat
HK1 NM_000188 ggtgaaatcgtccgcaac cccgggtcttcatcgtc
HK2 NM_000189 cggccgtgctacaatagg ctcgggatcatgtgaggg
Ki67 NM_002417 tcccgcctgttttctttctgac ctctccaaggatgatgatgctttac
TK1 NM_003258 gccgatgttctcaggaaaaagc gcgagtgtctttggcatacttg
doi: 10.1371/journal.pone.0085126.t001
Results
Effect of carboplatin and paclitaxel treatment on A2780
tumor growth
Treatment of mice implanted with A2780 xenograft tumors
with a combination of carboplatin (40 mg/kg ip) and paclitaxel
(10 mg/kg iv) day 0 and 5 resulted in decrease in tumor size on
day 8 compared to a vehicle treated control group. Baseline
tumor size was 118±19 mm3 in the control group and 135±16
mm3 in the treatment group. Tumor volume in the control group
was 926±192 mm3 on day 8 and tumors in the carboplatin and
paclitaxel (CaP) group was 490±73 mm3 on day 8 which was
significantly less than the tumors in the control group (p=0.03)
(Figure 1).
FDG uptake in carboplatin and paclitaxel treated A2780
xenografts
On day 4 after initiation of treatment with carboplatin and
paclitaxel FDG SUVmax ratio was significantly lower in the
CaP group compared to the control group (105±4% vs
138±9%; p=0.002) and on day 8 the FDG SUVmax ratio was
lower in the CaP compared to the control group (125±13% vs
167±13%; p=0.05) (Figure 2). The FDG SUVmax uptake was
not significantly different between the treatment and control
group at baseline and day 1 after treatment start. On day 4
FDG SUVmean ratio was significantly lower in the CaP group
compared to the control group (103±4% vs 130±5%; p=0.001).
The FDG SUVmean uptake was not significantly different
between the treatment and control group at baseline and on
day 1 and 8 after treatment start.
Figure 1.  Effect of carboplatin and paclitaxel treatment on A2780 tumor growth.  Mice implanted with A2780 xenograft tumors
were treated with a combination of carboplatin (40 mg/kg ip) and paclitaxel (10 mg/kg iv) on day 0 and 5. Tumor sizes in the
carboplatin and paclitaxel group (n=14 tumors) were significantly different than in the control group (n=12 tumors) on day 8
(p=0.034). The tumor sizes were measured with microCT and presented as mean±SEM.
doi: 10.1371/journal.pone.0085126.g001
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FLT uptake in carboplatin and paclitaxel treated A2780
xenografts
On day 1 the uptake of FLT SUVmax ratio was 89±9% in the
CaP group compared to 109±6% in the control group; however
the difference was not statistically significant (p=0.08) (Figure
3). At all other time points the FLT SUVmax uptake in the CaP
group was comparable to the control group. On day 1 the
uptake of FLT SUVmean ratio was lower in the CaP compared
with the control group (96±6% vs 113±5%; p=0.05). At all other
time points no difference was observed between the treatment
and control group.
Gene expression of GLUT1, HK1, HK2, Ki67 and TK1
The two most stably expressed reference genes were beta-
glucuronidase (GUSB) and hypoxanthine
phosphoribosyltransferase 1 (HPRT). The levels of the GOIs
were therefore normalized to the geometric mean of GUSB and
HPRT. In the treatment group GLUT1 expression was 67±10%
compared to 100±16% in the control group on day 8; however,
the difference was not statistically significant (p=0.08). In the
treatment group HK1 expression was 79±4% compared to
100±8% in the control group on day 8 which was statistically
significant (p=0.03) (Figure 4). No differences in expression of
HK2, Ki67 and TK1 were observed between the treatment and
control groups on day 8.
Discussion
In this study we describe the non-invasive imaging of
glucose uptake and cell proliferation for early assessment of
treatment response in a pre-clinical mouse model of human
ovarian cancer treated with a combination of carboplatin and
paclitaxel. Glucose uptake and cell proliferation were visualized
by FDG and FLT PET respectively. The A2780 cell line was
used for generation of xenograft tumors in mice. This tumor
model responded well to the combination therapy with
carboplatin and paclitaxel measured as a reduction in tumor
Figure 2.  FDG uptakes after treatment with carboplatin and paclitaxel.  FDG uptake was analyzed one hour post injection in a
carboplatin/paclitaxel treatment (n=8 tumors) and a control group (n=5 tumors). The mice were PET/CT scanned at baseline before
treatment start and day 1, 4 and 8 after injection of first dose. A) Tumor uptake of FDG during treatment of A2780 xenograft tumors
with carboplatin and paclitaxel. Quantitative tumor uptake is presented as SUVmean and SUVmax (mean±SEM). B) Representative
PET/CT images of one mouse from the carboplatin and paclitaxel treatment group (upper images) and one mouse from the control
vehicle treated group (lower images). Dotted circles indicate the tumors.
doi: 10.1371/journal.pone.0085126.g002
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size as compared with a control group on day 8 after start of
treatment.
On day 4 after start of treatment with carboplatin and
paclitaxel, uptake of FDG was significantly lower in the
treatment compared to the control group and uptake remained
low on day 8. The decrease in FDG uptake was paralleled by
decreases in GLUT1 and HK1 expression, whereas no change
in HK2 expression was observed suggesting that GLUT1 and
HK1 are involved in the FDG uptake in this tumor model.
We observed an early but transient decrease in cell
proliferation measured by FLT PET after treatment initiation of
responding A2780 tumors with the combination of carboplatin
and paclitaxel. A difference in FLT uptake between the
treatment and control group was already observed on day 1
after treatment start. In contrast, FLT uptake was not different
between the treatment and control mice on day 4 and 8 after
treatment start. The identical cell proliferation in the treatment
and control group measured by FLT PET on day 8 was
supported by gene expression measurements of Ki67 and TK1
which showed no difference in Ki67 and TK1 expression
between the treatment and control group on day 8. In other
studies, no change in FLT uptake, despite treatment with an
effective anti-cancer therapy, has also been observed [29,31].
The unchanged FLT uptake late in the treatment course could
be due to several factors. The anti-cancer treatment may result
in feedback activation of the de novo pathway of DNA
synthesis resulting in unchanged or even increased FLT uptake
despite decreased cell proliferation. This phenomenon has for
example been observed during treatment with 5-FU [35]. The
relation between the pyrimidine salvage pathway and the de
novo pathway of DNA synthesis in tumors has a great influence
on the uptake of FLT and different tumors have variable
contributions of the two pathways [50,51]. Some tumors rely
mainly on de novo synthesis of DNA precursors which will
result in low baseline FLT uptake despite high cell proliferation
rate [9]. Therefore it is possible that treatment of tumors relying
Figure 3.  FLT uptakes after treatment with carboplatin and paclitaxel.  FLT uptake was analyzed one hour post injection in a
carboplatin/paclitaxel treatment (n=6 tumors) and a control group (n=7 tumors). The mice were PET/CT scanned at baseline before
treatment start and day 1, 4 and 8 after injection of first dose. A) Tumor uptake of FLT during treatment of A2780 xenograft tumors
with carboplatin and paclitaxel. Quantitative tumor uptake is presented as SUVmean and SUVmax (mean±SEM). B) Representative
PET/CT images of one mouse from the carboplatin and paclitaxel treatment group (upper images) and one mouse from the control
vehicle treated group (lower images). On the images of the mouse from the treatment group two tumors are visible whereas on the
images of the control mouse only one tumor is visible. Dotted circles indicate the tumors.
doi: 10.1371/journal.pone.0085126.g003
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primarily on de novo synthesis not necessarily will result in
decreases in FLT uptake despite treatment with effective
chemotherapy that reduces cell proliferation [31]. Previously,
we have reported that effective anti-cancer treatment reduced
FLT uptake in the A2780 human ovarian cancer xenograft
mouse model indicating that the salvage pathway contributes
to the thymidine requirement in this tumor model [46,47,52]. No
decrease in the cell proliferation associated genes Ki67 and
TK1 were observed on day 8 despite effective treatment. Thus,
it seems likely that the combined treatment with carboplatin
and paclitaxel does not change the cell proliferation late in the
treatment course even though the therapy reduces the tumor
growth. Carboplatin and paclitaxel were administered by
injection on day 0 and 5. PET imaging was performed on day 4
and 8 and thus tracer uptake was measured on day 4 after the
1st and on day 3 after the 2nd administration of chemotherapy.
This may suggest that the treatment does decrease cell
proliferation for less than 3 days and this is the reason why no
difference in cell proliferation was observed on day 4 and 8
because the tumor cells has started to re-proliferate. Further
investigations are needed to determine for how long the
proliferation is affected after a single injection of carboplatin
and paclitaxel.
Both carboplatin and paclitaxel cause cell cycle arrest in the
G2/M phase. Phosphorylation of FLT by TK1 is assumed to be
the limiting factor for FLT uptake and activity of TK1 is
correlated with FLT uptake [13]. TK1 is mainly expressed in the
S-phase of cell cycle, therefore cell cycle arrest later in the cell
cycle might not influence uptake of FLT.
The differences between cell proliferation and glucose
uptake after initiation of carboplatin and paclitaxel therapy
illustrates the importance of combining imaging of several
physiological processes in order to analyze the biological effect
of cancer treatment. Carboplatin and paclitaxel treatment
induced significant decreases in FDG uptake after day 4 and
onwards but was less effective in reducing tumor cell
proliferation as measured by FLT. However FLT was an earlier
marker than FDG, although transient. Also this underscores the
importance of optimal timing between treatment and FLT or
FDG imaging since treatment response may otherwise be
overlooked. Thus, in order to find an imaging biomarker that
potentially could be predictive for treatment outcome in future
clinical studies different imaging biomarkers, giving information
of different physiological processes, need to be evaluated.
One of the main limitations of the present study was that a
limited number of animals were included in each group. This
could be the reason that several of the measurements did not
reach statistical significance due to type II error. Furthermore
does the present study describe treatment response monitoring
in human xenograft tumors in nude mice. Although the tumors
are of human origin, the non-human host environment may
cause that results acquired in this pre-clinical model not
necessarily can be translated into clinical studies. Another
limitation of the study was that the molecular markers were
measured on the gene expression level and it is therefore
unknown whether or not the gene expression levels are a
reflection of the protein expression.
A future application of treatment response monitoring with
FDG and FLT for ovarian cancer could potentially be evaluation
of treatment effect in protocols evaluating the effect of adding
e.g. targeted anti-cancer agents to the carboplatin and
paclitaxel standard therapy. Future studies are needed to
determine if FDG and FLT PET are applicable for prediction
and monitoring the outcome of supplementary combination in
comparison with a standard treatment.
In conclusion, we found that the change of FDG and FLT
uptake after initiation of therapy with carboplatin and paclitaxel
were different but complementary. FLT provides an early and
Figure 4.  Gene expression of GLUT1, HK1, HK2, Ki67 and TK1.  On day 8 immediately after the last PET/CT scan all tumors
were excised and total RNA was isolated and afterward revers transcribed into cDNA. With qPCR relative expression of GLUT1,
HK1, HK2, Ki67 and TK1 were measured. The levels of the gene of interests were normalized to the geometric means of two
reference genes GUSB and HPRT. A) For the FDG study GLUT1 expression was decreased, the difference not being statistically
significant (p=0.08), HK1 expression was lower in the treatment compared to the control group (p=0.03). B) For the FLT study no
difference in Ki67 and TK1 between the treatment and control group was observed on day 8. The data are presented as mean
±SEM.
doi: 10.1371/journal.pone.0085126.g004
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transient signal and FDG a later and more prolonged response.
Thus, our data suggest that both FDG and FLT PET may be
used for the assessment of anti-tumor effects of a combination
of carboplatin and paclitaxel in the treatment of ovarian cancer.
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